Featured Research

from universities, journals, and other organizations

Gene Expression Ratio Identifies Risk Of Recurrence In Breast Cancer Patients Receiving Tamoxifen

Date:
June 8, 2004
Source:
Massachusetts General Hospital
Summary:
A simple measurement of the expression levels of two genes in breast cancer tissue appears to identify tumors that are more likely to recur in women treated with tamoxifen for early-stage disease. Determining patients for whom tamoxifen treatment is likely to fail would allow earlier use of other therapies that could be more effective for those women.

BOSTON (June 3, 2004) -- A simple measurement of the expression levels of two genes in breast cancer tissue appears to identify tumors that are more likely to recur in women treated with tamoxifen for early-stage disease. Determining patients for whom tamoxifen treatment is likely to fail would allow earlier use of other therapies that could be more effective for those women.

Related Articles


Researchers from the Massachusetts General Hospital (MGH) Cancer Center and Arcturus Bioscience, Inc., describe their findings in a report to be published in the June issue of Cancer Cell. The paper is being released online today because related material is being presented at the June 5-8 American Society for Clinical Oncology meeting. The study was supported by grants from the Avon Foundation, the U.S. Department of Defense, and the National Cancer Institute.

Tamoxifen, which blocks the interaction between the hormone estrogen and its receptor protein, is used to treat breast cancers that express the estrogen receptor. However, only two thirds of these patients have a prolonged response to the drug. "Until now, there has been no way to predict which estrogen-receptor-positive patients will not respond to tamoxifen treatment," says Dennis Sgroi, MD, director of Breast Pathology at MGH who led the hospital's research team. "Identifying those for whom tamoxifen is likely to fail could allow physicians to choose other drugs, for instance the aromatase inhibitors that more completely block estrogen's action." Sgroi is an associate professor of Pathology at Harvard Medical School.

The hormone estrogen can stimulate both the normal growth of breast tissue and the uncontrolled growth of breast cancer. Cells from most breast tumors contain estrogen receptor molecules, indicating that the tumor's growth is likely to be sensitive to the hormone's action. Estrogen-blocking drugs have been used in recent years to prevent hormone-sensitive breast tumors from recurring after surgery and to treat metastasis. More than 500,000 U.S. women currently take tamoxifen, making it the most frequently used drug of this class.

The MGH and Arcturus research teams have collaborated for several years on studies of the molecular characteristics of breast tumors. Last year they published a study showing that advanced analysis technologies that identify which genes are expressed, or "turned on," in tumors can characterize the tumor's aggressiveness. As a follow-up to that work, the research teams led by Sgroi and Mark Erlander, PhD, Arcturus chief scientific officer, began to investigate whether such molecular signatures could help identify which drugs would be the best options for particular patients.

The researchers gathered tumor samples from patients who had received tamoxifen treatment for early-stage, estrogen-receptor-positive breast cancer. They identified 60 frozen samples suitable for gene expression analysis for which clinical follow-up information was available. Of those 60 patients, 32 had remained disease-free for an average of eight years, while 28 had recurrence of their tumor or metastasis.

Expression profile analysis demonstrated that the ratio between the expression levels of two genes - HOXB13 and IL17BR - was the strongest predictor of whether a tumor would recur. The higher the expression level of HOXB13 and the lower the expression of IL17BR, the greater the chance of tumor recurrence. Data from an additional 20 samples of tamoxifen-treated tumors supported the predictive power of the two-gene expression ratio.

"Many clinical laboratories currently have the capability to utilize Arcturus technology to measure the relative expression of these two genes," says Erlander. "Several centralized laboratories are developing a test that will be available this summer."

Because HOXB13 is known to be overexpressed in some breast tumors, the researchers investigated whether the gene might also play a role in tumor development. Using cells from normal breast tissues, they induced the expression of the HOXB13 gene. Cells in which the gene was activated showed obvious structural changes and appeared to have an increased ability to move and invade other tissues, characteristics of tumor cells. While that result must be confirmed by future studies, it suggests that the pathway controlled by HOXB13 could be a new therapeutic target.

The report's co-authors are first author Xiao-Jun Ma, PhD, Ranelle Salunga, J. Todd Tuggle, Yen Tran, Diem Tran, Ana Sollberger, Paul Amon, Wilson Wang, Wei Wang, Kimberly Stecker, Eden Estepa-Sabal and Thomas Baer, PhD, of Arcturus; Zuncai Wang, PhD, Paula Ryan, MD, PhD, Anne Barmettler, Andrew Fuller, Beth Muir, Gayatry Mohapatra, PhD, Barbara Smith, MD, PhD, Jerry Younger, MD, Ulysses Balis, MD, Atul Bhan, MD, Karleen Habin, RN, and Daniel Haber, MD, PhD, of the MGH; and Steven Isakoff, MD, PhD, and Joan Brugge, PhD, of Harvard Medical School.

Massachusetts General Hospital, established in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $400 million and major research centers in AIDS, cardiovascular research, cancer, cutaneous biology, medical imaging, neurodegenerative disorders, transplantation biology and photomedicine. In 1994, MGH and Brigham and Women's Hospital joined to form Partners HealthCare System, an integrated health care delivery system comprising the two academic medical centers, specialty and community hospitals, a network of physician groups, and nonacute and home health services.

Arcturus Bioscience, Inc., the leading company in laser microdissection instruments and reagents for the analysis of microscopic tissue samples. These tools enable researchers to perform rapid cell-based analysis of disease progression utilizing the smallest and purest samples possible to date. The company has developed this unique technology platform for genetic analysis of biopsy samples and has applied its platform to discover cell-specific gene signatures associated with human diseases such as cancer. Arcturus is a private company headquartered in Mountain View, California.


Story Source:

The above story is based on materials provided by Massachusetts General Hospital. Note: Materials may be edited for content and length.


Cite This Page:

Massachusetts General Hospital. "Gene Expression Ratio Identifies Risk Of Recurrence In Breast Cancer Patients Receiving Tamoxifen." ScienceDaily. ScienceDaily, 8 June 2004. <www.sciencedaily.com/releases/2004/06/040604025906.htm>.
Massachusetts General Hospital. (2004, June 8). Gene Expression Ratio Identifies Risk Of Recurrence In Breast Cancer Patients Receiving Tamoxifen. ScienceDaily. Retrieved October 24, 2014 from www.sciencedaily.com/releases/2004/06/040604025906.htm
Massachusetts General Hospital. "Gene Expression Ratio Identifies Risk Of Recurrence In Breast Cancer Patients Receiving Tamoxifen." ScienceDaily. www.sciencedaily.com/releases/2004/06/040604025906.htm (accessed October 24, 2014).

Share This



More Health & Medicine News

Friday, October 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Breakfast Debate: To Eat Or Not To Eat?

Breakfast Debate: To Eat Or Not To Eat?

Newsy (Oct. 23, 2014) Conflicting studies published in the same week re-ignited the debate over whether we should be eating breakfast. Video provided by Newsy
Powered by NewsLook.com
Ebola Fears Keep Guinea Hospitals Empty

Ebola Fears Keep Guinea Hospitals Empty

AP (Oct. 23, 2014) Fears of Ebola are keeping doctors and patients alike away from hospitals in the West African nation of Guinea. (Oct. 23) Video provided by AP
Powered by NewsLook.com
Despite Rising Death Toll, Many Survive Ebola

Despite Rising Death Toll, Many Survive Ebola

AP (Oct. 23, 2014) The family of a Dallas nurse infected with Ebola in the US says doctors can no longer detect the virus in her. Despite the mounting death toll in West Africa, there are survivors there too. (Oct. 23) Video provided by AP
Powered by NewsLook.com
Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Working Mother (Oct. 22, 2014) Is your child ready? Video provided by Working Mother
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins